LIVE WEBINAR: Thursday, February 2, 2023, 5:00 PM – 6:00 PM Eastern Time

Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, February 2nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Farrukh T Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C Simmons Comprehensive Cancer Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Kerry A Rogers, MD
Associate Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Thursday, February 2, 2023
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Structural and pharmacologic similarities and differences among Bruton tyrosine kinase (BTK) inhibitors
  • MODULE 2: Spectrum, incidence, and severity of hematologic and nonhematologic toxicities
  • MODULE 3: Guideline and expert recommendations for the management of hematologic and nonhematologic BTK inhibitor side effects
  • MODULE 4: Tolerability observed with BTK inhibitors in combination with other systemic anticancer therapies

Target Audience
This activity is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of cancer with BTK inhibitors.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the approved Bruton tyrosine kinase (BTK) inhibitors to better understand the activity and toxicities associated with these agents.
  • Appreciate the frequency and severity of various therapy-related cardiologic adverse events (AEs) commonly encountered by patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia or mantle cell lymphoma, and develop strategies to optimally care for individuals experiencing these complications.
  • Understand the pathophysiology of hematologic AEs associated with BTK inhibitors, and use this knowledge to identify, manage and mitigate these side effects.
  • Recall commonly encountered nonhematologic AEs associated with BTK inhibitors, and appropriately intervene for patients when toxicities are suspected or diagnosed.
  • Compare and contrast the side-effect and toxicity profiles of the various FDA-approved BTK inhibitors, and recall the patient- and disease-specific factors affecting the decision to commence treatment with one versus the others.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr AwanAdvisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Cardinal Health, Caribou Biosciences Inc, Celgene Corporation, Cellectar Biosciences Inc, DAVA Oncology, Epizyme Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Verastem Inc; Contracted Research: Pharmacyclics LLC, an AbbVie Company. Dr RogersConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Travel: AstraZeneca Pharmaceuticals LP.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.